COMPAS: A Phase III Study to Demonstrate Efficacy of GSK Biologicals' 10-valent Pneumococcal Vaccine (GSK1024850A) Against Community Acquired Pneumonia and Acute Otitis Media

Trial Profile

COMPAS: A Phase III Study to Demonstrate Efficacy of GSK Biologicals' 10-valent Pneumococcal Vaccine (GSK1024850A) Against Community Acquired Pneumonia and Acute Otitis Media

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Oct 2016

At a glance

  • Drugs Pneumococcal 10-valent vaccine conjugate (Primary) ; Hepatitis A vaccine inactivated; Hepatitis B vaccine recombinant; Hib-DTaP-hepatitis B-poliovirus vaccine; Hib-DTaP-poliovirus vaccine
  • Indications Community-acquired pneumonia; Hepatitis A; Hepatitis B; Otitis media; Pneumococcal infections; Pneumonia
  • Focus Registrational; Therapeutic Use
  • Acronyms COMPAS
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 08 Jul 2011 Actual end date (Jun 2011) added as reported by ClinicalTrials.gov.
    • 08 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top